Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Pharmacol. 2004 Jun;4(3):263-72.

COPD: is there light at the end of the tunnel?

Author information

1
National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK. p.j.barnes@imperial.ac.uk

Abstract

No currently available treatments reduce the progression or suppress the inflammation of chronic obstructive pulmonary disease (COPD). However, with a better understanding of the inflammatory and destructive process, several targets have been identified and new treatments are in clinical development. Several specific therapies are directed against the influx of inflammatory cells into the airways and lung parenchyma that occurs in COPD, including adhesion molecule and chemokine-directed therapy, as well as therapies to inhibit tumour necrosis factor-alpha. Several broad-spectrum anti-inflammatory drugs are also in development, and include inhibitors of phosphodiesterase-4, p38 mitogen-activated protein kinase and nuclear factor-kappaB. There is a need for validated biomarkers and monitoring techniques in early clinical studies with new therapies for COPD.

PMID:
15140418
DOI:
10.1016/j.coph.2004.03.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center